Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.

Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.

Building a robotics infrastructure "is the only way to make sure we generate data of sufficient quality at the speed and scale required, and now everybody in the pharma industry is very excited about the idea of end-to-end automation." So says Martin-Immanuel Bittner, CEO of Arctoris.

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.